{"log_id": 7394884950128119567, "direction": 0, "words_result_num": 43, "words_result": [{"probability": {"variance": 0.000622, "average": 0.990786, "min": 0.876406}, "location": {"width": 724, "top": 218, "height": 33, "left": 242}, "words": "托莫西汀主要通过CYP2D6途径代谢为4羟基托莫西汀。在EM中,选择性的"}, {"probability": {"variance": 0.004219, "average": 0.98588, "min": 0.57119}, "location": {"width": 752, "top": 258, "height": 31, "left": 213}, "words": "YP2D6抑制剂使托莫西汀稳态浓度与PM相近。当联合使用CYP2D6抑制剂(如帕罗西"}, {"probability": {"variance": 0.000369, "average": 0.992068, "min": 0.896522}, "location": {"width": 761, "top": 295, "height": 33, "left": 204}, "words": "汀、氟西汀和奎尼丁)时,有必要调节盐酸托莫西汀的剂量。在个别联合使用帕罗西汀或"}, {"probability": {"variance": 0.001897, "average": 0.979491, "min": 0.770545}, "location": {"width": 639, "top": 336, "height": 26, "left": 205}, "words": "氟西汀的EM中,托莫西汀的AUC大约高6至8倍,Css、Cmax高3至4倍"}, {"probability": {"variance": 0.000243, "average": 0.995962, "min": 0.902987}, "location": {"width": 721, "top": 374, "height": 27, "left": 244}, "words": "在体外研究中显示,在PM中联合使用细胞色素P450抑制剂不会提高托莫西汀的血浆"}, {"probability": {"variance": 1e-05, "average": 0.996785, "min": 0.993648}, "location": {"width": 42, "top": 414, "height": 23, "left": 204}, "words": "浓度"}, {"probability": {"variance": 0.00016, "average": 0.991918, "min": 0.951824}, "location": {"width": 256, "top": 450, "height": 25, "left": 203}, "words": "抗高血压药物和收缩血管药物"}, {"probability": {"variance": 0.000526, "average": 0.993971, "min": 0.858681}, "location": {"width": 722, "top": 487, "height": 26, "left": 242}, "words": "因为可能影响血压,与抗高血压药物和收缩血管药物(如多巴胺、多巴酚丁胺)或其"}, {"probability": {"variance": 1.2e-05, "average": 0.997773, "min": 0.986735}, "location": {"width": 312, "top": 527, "height": 25, "left": 203}, "words": "他增加血压的药物合用时,应该慎用"}, {"probability": {"variance": 0.035378, "average": 0.865939, "min": 0.599939}, "location": {"width": 82, "top": 565, "height": 25, "left": 202}, "words": "沙丁酵"}, {"probability": {"variance": 0.000263, "average": 0.993523, "min": 0.9214}, "location": {"width": 712, "top": 603, "height": 25, "left": 238}, "words": "盐酸托莫西汀胶囊应慎用于正在接受全身给药(口服或静脉输注)沙丁胺醇(或其他"}, {"probability": {"variance": 0.000556, "average": 0.992067, "min": 0.874684}, "location": {"width": 754, "top": 641, "height": 28, "left": 198}, "words": "β2受体激动剂)治疗的患者,因为沙丁肢醇对心血管系统的作用可能增强,从而导致心率"}, {"probability": {"variance": 0.00351, "average": 0.969733, "min": 0.805657}, "location": {"width": 191, "top": 680, "height": 24, "left": 206}, "words": "和血压升高,沙丁胺醇"}, {"probability": {"variance": 0.002923, "average": 0.985061, "min": 0.71841}, "location": {"width": 497, "top": 679, "height": 25, "left": 462}, "words": "g静脉注射2小时以上)引起心率和血压的增高。托莫西汀"}, {"probability": {"variance": 0.000109, "average": 0.994296, "min": 0.94462}, "location": {"width": 738, "top": 716, "height": 27, "left": 225}, "words": "0mg每日二次服用5天)可加强这些作用,在联合使用沙丁胺醇和托莫西汀的初期最明"}, {"probability": {"variance": 0.002488, "average": 0.983824, "min": 0.696161}, "location": {"width": 752, "top": 752, "height": 31, "left": 205}, "words": "显。然而,另一项研究中,21名排除了弱代谢状态的健康亚裔受试者合用吸入性沙丁胺醇"}, {"probability": {"variance": 0.005828, "average": 0.972315, "min": 0.523624}, "location": {"width": 744, "top": 790, "height": 31, "left": 205}, "words": "(0-800mcg)与托莫西汀(每次80mg,每日一次,连用5天)后,未观察到对心率和血"}, {"probability": {"variance": 0.000265, "average": 0.988438, "min": 0.956093}, "location": {"width": 116, "top": 832, "height": 23, "left": 204}, "words": "压的上述影响"}, {"probability": {"variance": 0.003932, "average": 0.977911, "min": 0.761759}, "location": {"width": 228, "top": 885, "height": 25, "left": 203}, "words": "托莫西汀对P450m的影响"}, {"probability": {"variance": 0.00842, "average": 0.977288, "min": 0.453116}, "location": {"width": 695, "top": 921, "height": 27, "left": 243}, "words": "托莫西汀不会产生具有临床意义的对P450酶的抑制或削弱,包括CYP1A2"}, {"probability": {"variance": 0.000146, "average": 0.987715, "min": 0.960141}, "location": {"width": 244, "top": 964, "height": 21, "left": 207}, "words": "CYP3A、CYP2D6和CYP2C9"}, {"probability": {"variance": 0.003263, "average": 0.979327, "min": 0.683486}, "location": {"width": 719, "top": 993, "height": 34, "left": 245}, "words": "CYP3A底物(如咪唑安定)一联合使用盐酸托莫西汀(60 mg BID服用12天)和咪唑"}, {"probability": {"variance": 0, "average": 0.999209, "min": 0.998711}, "location": {"width": 41, "top": 1040, "height": 21, "left": 205}, "words": "安定"}, {"probability": {"variance": 0.0004, "average": 0.992145, "min": 0.892709}, "location": {"width": 680, "top": 1033, "height": 31, "left": 283}, "words": "种典型的被CYP3A4代谢的药物,单剂量5mg),结果显示,咪唑安定的AUC有"}, {"probability": {"variance": 1.1e-05, "average": 0.997247, "min": 0.987974}, "location": {"width": 524, "top": 1072, "height": 29, "left": 209}, "words": "5%的增高。对于通过CYP3A代谢的药物没有剂量调节的建议"}, {"probability": {"variance": 0.002718, "average": 0.978405, "min": 0.748909}, "location": {"width": 719, "top": 1108, "height": 28, "left": 246}, "words": "CYP2D6底物(如去甲丙咪嗪)一联合使用托莫西汀(40或60mg每日二次服用13"}, {"probability": {"variance": 0.007246, "average": 0.976442, "min": 0.473514}, "location": {"width": 752, "top": 1144, "height": 33, "left": 206}, "words": "天)和去甲丙咪嗪(一种典型的被CYP2D6代谢的药物,单剂量50mg)不改变去甲丙咪"}, {"probability": {"variance": 0.00424, "average": 0.975718, "min": 0.669849}, "location": {"width": 559, "top": 1181, "height": 30, "left": 206}, "words": "嗪药代动力学,对于经CYP2D6代谢的药物,没有剂量调节的建议"}, {"probability": {"variance": 0.084859, "average": 0.70869, "min": 0.417384}, "location": {"width": 35, "top": 1228, "height": 23, "left": 208}, "words": "乙"}, {"probability": {"variance": 0.014138, "average": 0.495229, "min": 0.374932}, "location": {"width": 91, "top": 1209, "height": 31, "left": 778}, "words": "黎动"}, {"probability": {"variance": 0.013028, "average": 0.969419, "min": 0.424917}, "location": {"width": 481, "top": 1257, "height": 31, "left": 244}, "words": "同时使用盐酸托莫西汀和乙醇,并不改变乙醇的兴奋作"}, {"probability": {"variance": 1.8e-05, "average": 0.995593, "min": 0.991319}, "location": {"width": 211, "top": 1211, "height": 81, "left": 762}, "words": "公司"}, {"probability": {"variance": 0.000745, "average": 0.976704, "min": 0.938398}, "location": {"width": 147, "top": 1250, "height": 43, "left": 929}, "words": "广州药"}, {"probability": {"variance": 0.072919, "average": 0.801904, "min": 0.420017}, "location": {"width": 60, "top": 1301, "height": 23, "left": 205}, "words": "甲酯"}, {"probability": {"variance": 0.048244, "average": 0.842065, "min": 0.531438}, "location": {"width": 174, "top": 1290, "height": 34, "left": 898}, "words": "有限公"}, {"probability": {"variance": 0.004921, "average": 0.983697, "min": 0.586137}, "location": {"width": 655, "top": 1329, "height": 32, "left": 244}, "words": "与单独服用哌甲酯相比,盐酸托莫西汀与哌甲酯合用并不增加对心血管的影响"}, {"probability": {"variance": 6.9e-05, "average": 0.992341, "min": 0.972715}, "location": {"width": 214, "top": 1373, "height": 27, "left": 206}, "words": "高血浆蛋白结合率的药物"}, {"probability": {"variance": 3.3e-05, "average": 0.997801, "min": 0.965129}, "location": {"width": 720, "top": 1403, "height": 35, "left": 245}, "words": "在体外研究中,进行了托莫西汀和高血浆蛋白结合率药物在治疗浓度下的药物置换研"}, {"probability": {"variance": 0.003149, "average": 0.986767, "min": 0.645312}, "location": {"width": 758, "top": 1441, "height": 34, "left": 207}, "words": "究。托莫西汀不影响华法令、乙酰水杨酸、苯妥英钠或安定与人白蛋白的结合。同样,这"}, {"probability": {"variance": 0.000176, "average": 0.993379, "min": 0.941328}, "location": {"width": 386, "top": 1482, "height": 31, "left": 206}, "words": "些化合物也不影响托莫西汀与人白蛋白的结合"}, {"probability": {"variance": 0, "average": 0.752684, "min": 0.752684}, "location": {"width": 56, "top": 1531, "height": 32, "left": 924}, "words": "烧"}, {"probability": {"variance": 0.080843, "average": 0.710472, "min": 0.426143}, "location": {"width": 26, "top": 1575, "height": 27, "left": 652}, "words": "8"}, {"probability": {"variance": 0.04998, "average": 0.864094, "min": 0.476878}, "location": {"width": 143, "top": 1600, "height": 36, "left": 1013}, "words": "仪供存档"}], "language": 3}